Overexpression of lncRNA SNGH3 Predicts Unfavorable Prognosis and Clinical Outcomes in Human Cancers: Evidence from a Meta-Analysis

Figure 6

Validation of the role of lncRNA SNHG3 in human cancers in the TCGA dataset: (a) the expression of SNHG3 in cancers and normal tissues, BLCA (bladder urothelial carcinoma), CHOL (cholangiocarcinoma), COAD (colon adenocarcinoma), ESCA (esophageal carcinoma), and LIHC (liver hepatocellular); (b) the expression of SNHG3 in cancers and normal tissues, LUAD (lung adenocarcinoma), LUSC (lung adenocarcinoma), PRAD (prostate adenocarcinoma), READ (rectum adenocarcinoma), STAD (rectum adenocarcinoma), and UCEC (uterine corpus); (c) violin plot of clinical stage of SNHG3 expression in human pancancers; (d) overall survival plot of SNHG3; (e) disease-free survival plot of SNHG3.

(a)

(b)

(c)

(d)

(e)